Regulatory Intelligence

GLP-1 RA Regulatory Updates

Chronological regulatory actions, safety communications, and label updates from FDA, EMA, and MHRA.

Updated Weekly
15 Recent Updates
FDA US Food & Drug Administration
EMA European Medicines Agency
MHRA UK Medicines & Healthcare products
FDA New Indication Approval February 1, 2026
FDA approves tirzepatide for obstructive sleep apnea (OSA)
Tirzepatide (Zepbound)
High Impact

Summary

FDA approved tirzepatide as the first pharmacologic treatment for obstructive sleep apnea (OSA) in adults with obesity. Based on SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index (

Key Details

  • Approved for moderate-to-severe OSA in adults with obesity (BMI ≥30)
  • SURMOUNT-OSA trial: 55-60% reduction in AHI vs placebo at 52 weeks
  • Can be used as monotherapy or adjunct to CPAP
  • Recommended duration: Long-term chronic treatment
  • Dosing: Same as obesity indication (2.5 mg start, titrate to 15 mg)
View Official Source
EMA Pharmacovigilance Update January 28, 2026
EMA concludes review: No causal link between GLP-1 RAs and suicidal ideation
All GLP-1 RAs
High Impact

Summary

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) completed comprehensive review of suicidal ideation and self-harm risk. Concluded no causal relationship established; product information to be updated with reassuring data.

Key Details

  • Review of 15+ years of postmarketing data across all approved GLP-1 RAs
  • Analysis of >20 million patient-years of exposure
  • No consistent signal across trials or real-world evidence
  • Rates of suicidal ideation comparable to background population
  • Product labeling to include: 'Available evidence does not support causal association'
FDA Safety Communication January 15, 2026
Updated perioperative management guidance (January 2026)
All GLP-1 RAs
High Impact

Summary

FDA issued comprehensive perioperative management recommendations for patients on GLP-1 RAs undergoing elective and emergency surgery. Addresses aspiration risk and glycemic management.

Key Details

  • Elective surgery: Weekly formulations (semaglutide, tirzepatide, dulaglutide) - withhold 1 week prior; Daily formulations (liraglutide) - withhold on day of procedure; Oral semaglutide - withhold 1 day prior
  • Emergency surgery: Proceed with rapid sequence induction; inform anesthesiologist
  • Glycemic monitoring: Check blood glucose pre-op and post-op
  • Resume GLP-1 RA when oral intake tolerated (typically 24-48 hours post-op)
View Official Source
FDA Label Update February 5, 2026
Updated cardiovascular indication language
Semaglutide (Wegovy)
High Impact

Summary

FDA approved updated labeling to include SELECT trial data demonstrating 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity or overweight and established cardiovascular disease but without diabetes.

Key Details

  • New indication: To reduce risk of CV death, non-fatal MI, and non-fatal stroke in adults with established CVD and obesity/overweight
  • Based on SELECT trial (n=17,604): HR 0.80 (95% CI 0.72-0.90, p<0.001)
  • First weight management drug approved for CV risk reduction in non-diabetic population
EMA New Indication Approval January 20, 2026
EU approval for chronic weight management
Tirzepatide (Mounjaro/Zepbound)
High Impact

Summary

EMA approved tirzepatide (Zepbound brand) for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

Key Details

  • Approved doses: 5 mg, 10 mg, 15 mg once weekly
  • Based on SURMOUNT-1 and -2 trials showing up to 22.5% weight loss
  • Marketing authorization valid in all 27 EU member states
FDA Safety Communication December 15, 2025
Updated warnings for suicidal ideation and behavior
All GLP-1 RAs
Moderate Impact

Summary

FDA concluded review of postmarketing reports of suicidal thoughts/behaviors in patients taking GLP-1 RAs. No causal relationship established, but enhanced monitoring recommended.

Key Details

  • Analysis of FAERS database (2018-2025): 265 reports of suicidal ideation, 35 suicide attempts
  • No signal detected in large RCT safety databases
  • Recommendation: Screen for depression/suicidality before and during treatment
  • No black box warning added
MHRA Safety Alert November 30, 2025
Aspiration risk during anesthesia with delayed gastric emptying
All GLP-1 RAs
Moderate Impact

Summary

MHRA issued safety alert regarding increased aspiration risk during general anesthesia/procedural sedation due to delayed gastric emptying.

Key Details

  • Case series: 18 UK reports of pulmonary aspiration during anesthesia (2022-2025)
  • Elective procedures: Daily formulations - withhold on day of procedure; Weekly formulations - withhold 1 week prior; Oral semaglutide - withhold 1 day prior
  • Emergency procedures: Rapid sequence induction with cricoid pressure recommended
FDA Drug Shortage Resolution October 22, 2025
All strengths of Mounjaro removed from shortage list
Tirzepatide (Mounjaro)
High Impact

Summary

FDA removed tirzepatide injection from the drug shortage database. All doses (2.5 mg - 15 mg) now consistently available.

Key Details

  • Eli Lilly production capacity fully restored after 18-month shortage
  • Compounding pharmacies must cease tirzepatide production within 60 days
  • Patient impact: Transition from compounded to FDA-approved product required
EMA Pharmacovigilance Update September 10, 2025
PRAC review: No causal link to thyroid cancer in humans
Semaglutide (Ozempic/Wegovy)
Low Impact

Summary

EMA concluded that rodent C-cell tumor findings do not translate to humans; existing boxed warning remains but epidemiological data reassuring.

Key Details

  • Analysis of 12+ years of postmarketing data (>5 million patient-years of exposure)
  • No increased incidence of medullary thyroid carcinoma (MTC) in humans
  • Mechanism: Rodent C-cells express high GLP-1R density; human C-cells have minimal/absent expression
  • Contraindication for personal/family history of MTC or MEN 2 remains (precautionary)
FDA Pediatric Indication Expansion August 15, 2025
Approved for chronic weight management in children 6-11 years
Liraglutide (Saxenda)
Moderate Impact

Summary

FDA approved liraglutide 3.0 mg for pediatric obesity (ages 6-11 years) with BMI ≥95th percentile.

Key Details

  • First GLP-1 RA approved for children under 12 years
  • Dosing: Start 0.6 mg daily, titrate to 3.0 mg (same as adults)
  • Trial: 82 children (age 6-<12), 56 weeks, BMI SDS reduction -0.22 vs -0.03 placebo
  • Requires multidisciplinary pediatric obesity management program

Looking for Historical Updates?

Regulatory updates from 2017-2024 are archived and available upon request.

FDA Drugs@FDA EMA Medicines Database MHRA Drug Safety Update

Data Sources: Official publications from FDA (Drug Safety Communications, MedWatch), EMA (PRAC recommendations), MHRA (Drug Safety Updates), and manufacturer press releases.

Update Frequency: Weekly review cycle. Critical safety alerts are added within 48 hours of publication.

Medical Disclaimer: This timeline is for educational purposes. Always verify regulatory status via official agency websites before clinical decision-making.

Last Updated: February 8, 2026 | Next Review: February 15, 2026